Boston Financial Mangement LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,923 shares of the medical instruments supplier’s stock after selling 995 shares during the period. Boston Financial Mangement LLC’s holdings in Becton, Dickinson and were worth $10,958,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Westwood Holdings Group Inc. raised its position in Becton, Dickinson and by 24.2% during the second quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock valued at $206,136,000 after purchasing an additional 205,721 shares in the last quarter. Colony Group LLC raised its position in Becton, Dickinson and by 2.1% during the second quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock valued at $2,320,000 after purchasing an additional 239 shares in the last quarter. State Street Corp raised its position in Becton, Dickinson and by 3.5% during the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after purchasing an additional 342,873 shares in the last quarter. Peapack Gladstone Financial Corp raised its position in Becton, Dickinson and by 1.3% during the second quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock valued at $7,116,000 after purchasing an additional 453 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its position in Becton, Dickinson and by 35.3% during the second quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock valued at $8,447,000 after purchasing an additional 11,300 shares in the last quarter. Institutional investors and hedge funds own 86.71% of the company’s stock.

In other news, EVP Ribo Alberto Mas sold 7,463 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $201.41, for a total transaction of $1,503,122.83. Following the transaction, the executive vice president now owns 29,323 shares in the company, valued at $5,905,945.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Linda M. Tharby sold 4,695 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total transaction of $941,253.60. Following the transaction, the executive vice president now owns 18,670 shares in the company, valued at approximately $3,742,961.60. The disclosure for this sale can be found here. Insiders have sold 69,933 shares of company stock worth $14,063,953 in the last quarter. Company insiders own 1.40% of the company’s stock.

Several research analysts have commented on the stock. Stifel Nicolaus restated a “buy” rating and set a $245.00 price objective on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Royal Bank Of Canada restated a “sector perform” rating and set a $230.00 price objective (up from $210.00) on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price objective for the company in a research report on Tuesday, October 31st. Finally, Wells Fargo & Company reaffirmed a “positive” rating and set a $235.00 target price (up previously from $225.00) on shares of Becton, Dickinson and in a research note on Tuesday, October 24th. They noted that the move was a valuation call. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Becton, Dickinson and currently has an average rating of “Buy” and a consensus target price of $213.47.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/08/becton-dickinson-and-company-bdx-shares-sold-by-boston-financial-mangement-llc.html.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at $221.27 on Wednesday. The company has a quick ratio of 5.01, a current ratio of 5.56 and a debt-to-equity ratio of 1.48. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $225.23. The firm has a market cap of $50,564.94, a price-to-earnings ratio of 23.41, a P/E/G ratio of 1.74 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. Becton, Dickinson and’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.12 earnings per share. analysts forecast that Becton, Dickinson and Company will post 10.6 EPS for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.